Does Insurance Cover Wegovy or Ozempic? What You Need to Know

The same active ingredient — semaglutide — is covered by approximately 85% of commercial insurance plans when prescribed as Ozempic for type 2 diabetes, and by approximately 45% of commercial plans when prescribed as Wegovy for weight loss. Same molecule. Dramatically different coverage rate. This asymmetry is the defining feature of the GLP-1 insurance landscape in 2026, and understanding it determines whether you pay $25 a month or $349 a month for the same medication.

This article covers the full insurance picture across commercial plans, Medicare, Medicaid, and employer plans — including 2026 policy changes, the specific documentation that makes the difference between approval and denial, and what to do when you are denied.

The Ozempic vs. Wegovy Coverage Asymmetry

Ozempic and Wegovy contain the same active ingredient — semaglutide — at similar doses. Their FDA approvals differ:

• Ozempic: Approved for type 2 diabetes management and cardiovascular risk reduction in patients with type 2 diabetes
• Wegovy: Approved for chronic weight management in adults with obesity or overweight with comorbidities

Because diabetes is a widely covered condition and weight loss medications have historically been excluded from many plans, insurers treat these identical molecules very differently based on the label and the prescribing indication.

The practical implication: If you have type 2 diabetes and your insurer covers Ozempic for diabetes but not Wegovy for weight loss, your prescribing clinician may prescribe Ozempic off-label for weight management — achieving the same clinical outcome through the covered indication. This is legal, common, and clinically appropriate when the patient has a documented T2D diagnosis. Ask your provider whether this pathway applies to your situation.

Commercial Insurance: What's Actually Covered

Coverage rates by insurer (2026)

Commercial insurance coverage for weight loss GLP-1s has improved since 2022 but remains inconsistent. As of 2026:

These are general patterns, not guarantees. Employer-sponsored plan designs override insurer defaults. The only way to confirm your specific coverage is to check your plan's formulary directly.

How to verify your coverage in five minutes

Step 1: Log into your insurer's member portal.

Step 2: Navigate to "drug formulary" or "prescription drug coverage."

Step 3: Search for "semaglutide," "Wegovy," "tirzepatide," or "Zepbound."

Step 4: Review the result:

• If the medication appears with a tier — it is on formulary. Prior authorization is almost certainly required, but coverage is possible.
• If the medication appears as excluded — your plan does not cover it. Prior auth is not an option under that plan design.
• If the medication does not appear at all — call member services to confirm whether it is covered.

Step 5: If covered, call member services and ask specifically: "What prior authorization criteria must be met for Wegovy?" Get the specific requirements in writing — BMI threshold, qualifying comorbidities, step therapy requirements, and lab documentation requirements. This is your roadmap for the PA submission.

Prior Authorization: The Process That Determines Your Cost

Prior authorization is required by virtually every commercial plan that covers GLP-1 weight loss medications. It is your insurer's process for verifying that the prescription is medically appropriate before approving coverage.

Standard PA requirements

Most plans require documentation of:

BMI: Usually 30 or higher (obesity), or 27 or higher with a qualifying comorbidity. The BMI must be documented in a recent clinical record — self-reported values from a telehealth questionnaire may not be sufficient.

Qualifying comorbidity (if BMI 27–29.9): Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease. The comorbidity must be documented with a diagnosis code in your medical records.

Prior weight loss attempts: Many plans require documentation that the patient has previously attempted diet and exercise modifications, and some require a structured weight loss program. Documentation should include dates, the nature of the intervention, and the outcome.

Step therapy (some plans): A requirement that you try a less expensive medication first. Common step therapy requires trial of phentermine, topiramate, or naltrexone/bupropion (Contrave) before approving a GLP-1. If you have tried these, document it. If you have not, ask your provider whether the step therapy requirement can be waived based on contraindications or clinical history.

Lab work: A1C, lipid panel, and basic metabolic panel are commonly required to document the metabolic picture.

Timeline

Standard prior authorization takes 3–10 business days from submission to decision. Urgent (expedited) review is typically 72 hours when a delay would significantly harm the patient. During this waiting period, your medication is not covered — most patients do not receive their first prescription until PA is approved.

What happens during review

The insurer's pharmacy benefits team (or a contracted PBM like CVS Caremark, Express Scripts, or OptumRx) reviews the PA submission. They are checking whether your documented clinical picture meets their specific coverage criteria — not the FDA criteria, which are broader. Insurer criteria are often stricter than FDA criteria.

When Insurance Denies: Your Appeal Rights

A denial is not the end. About 30–50% of well-documented insurance appeals succeed — a denial is the beginning of a negotiation, not a final answer. The key word is "well-documented." Poorly documented appeals fail at a much higher rate.

Step 1: Get the specific denial reason in writing

Your insurer must tell you exactly why your PA was denied. Common denial reasons include:

• "Not medically necessary" — usually means insufficient documentation of BMI, comorbidities, or prior weight loss attempts
• "Step therapy requirements not met" — requires trial of a first-line medication before GLP-1 approval
• "Not a covered benefit" — the plan explicitly excludes weight loss medications; appeals within the plan are unlikely to succeed
• "Requested medication not on formulary" — the specific drug is excluded; ask about a covered alternative

Step 2: Peer-to-peer review

If your PA is denied, your prescribing clinician can request a peer-to-peer review — a direct phone call between your doctor and the insurer's medical reviewer. This is the single most effective intervention for PA denials. According to GLP-1 access report data, 65%+ of appealed denials are overturned when properly documented. Peer-to-peer reviews conducted by clinicians who understand the insurer's specific criteria and can address the stated denial reason directly achieve better outcomes than written appeals alone.

Platforms with dedicated prior authorization concierge teams — Ro Body Program, WeightWatchers Clinic, Calibrate, and Mochi Health — actively manage peer-to-peer reviews on your behalf. At self-managed platforms like Hims/Hers, Sesame, or GoodRx, peer-to-peer review would require your prescribing clinician to initiate it independently.

Step 3: Formal written appeal

If peer-to-peer review does not resolve the denial, submit a formal written appeal with:

• Your complete medical records supporting the clinical need
• A letter from your prescribing physician specifically addressing the denial reason
• Published clinical guidelines (AHA, Endocrine Society, Obesity Medicine Association) supporting GLP-1 use in patients with your documented profile
• Evidence of prior weight loss attempts and their outcomes

Step 4: External review

If the internal appeal is denied, most states have a process for independent external review of coverage denials. The insurer's denial letter is required to explain your right to external review. Your state insurance commissioner's office can assist. For employer-sponsored self-insured plans, external review rights vary — your HR department and the plan's Summary Plan Description explain available options.

Step 5: Employer escalation

If your insurance is through an employer and the plan is self-insured, your employer's HR or benefits team has more influence over coverage decisions than a typical insured plan would. A formal request to HR — particularly if supported by a physician letter — can result in a coverage exception even when the standard PA process fails.

Medicare Coverage: A Rapidly Changing Landscape

The statutory exclusion (the baseline)

Federal law (Section 1927 of the Social Security Act) has historically prohibited Medicare Part D plans from covering drugs prescribed for weight loss, weight gain, or anorexia. This statutory exclusion is why Medicare could not cover Wegovy or Zepbound for weight loss even after FDA approval.

What Medicare covers right now (2026)

Ozempic, Mounjaro (for type 2 diabetes): Medicare Part D covers these medications under the diabetes indication when prescribed for T2D. Coverage is broad — most Part D plans include them on formulary, typically at Tier 3 or 4, with prior authorization. If you have Medicare and type 2 diabetes, Ozempic coverage is generally available through your Part D plan.

Wegovy (for cardiovascular risk reduction): In 2024, CMS updated guidance to allow Medicare Part D coverage of Wegovy when prescribed specifically for patients with established atherosclerotic cardiovascular disease (prior heart attack, stroke, or documented ASCVD) who are overweight or obese. This is not weight loss coverage — it is cardiovascular risk reduction coverage. If you have Medicare and established ASCVD, Wegovy may be covered under your Part D plan with prior authorization. As of April 2026, some Aetna Medicare Part D plans have begun covering Wegovy with a $50/month copay cap.

Zepbound (for obstructive sleep apnea): Medicare Part D covers Zepbound when prescribed for moderate-to-severe obstructive sleep apnea in adults with obesity. This is the OSA indication, not the weight loss indication.

The Medicare GLP-1 Bridge (July 2026)

The Medicare GLP-1 Bridge is a CMS demonstration program running from July 1 to December 31, 2026, that provides Medicare Part D beneficiaries access to Wegovy and Zepbound for weight loss at $50 per month. It operates outside the standard Part D benefit and requires prior authorization with BMI-based eligibility criteria.

This is a demonstration program with a finite duration. CMS plans to launch the BALANCE Model in January 2027, which would allow participating Part D plans to cover GLP-1 drugs for weight management as part of the standard Part D benefit.

If you have Medicare and want GLP-1 coverage for weight loss:

• If you have established cardiovascular disease: Pursue Wegovy coverage under the cardiovascular indication now
• If you have type 2 diabetes: Pursue Ozempic coverage under the diabetes indication now
• If you have obstructive sleep apnea and obesity: Pursue Zepbound coverage under the OSA indication now
• If you have none of these: The Medicare GLP-1 Bridge ($50/month for Wegovy and Zepbound) becomes available July 1, 2026 — confirm eligibility with your Part D plan

Important: Novo Nordisk and Eli Lilly manufacturer savings cards — which reduce cost to $25/month for commercially insured patients — are not available to Medicare or Medicaid beneficiaries under federal anti-kickback rules. Cash-pay pricing at NovoCare and LillyDirect is available to Medicare patients but not the savings card discount.

Employer-Sponsored Plans: The Wildcard

Employer plans — particularly large self-insured plans — operate with significant independence from the standard insurance coverage landscape. Unlike fully insured plans that must follow state insurance mandates, self-insured plans design their own benefit packages.

A 2025 KFF survey found that approximately 42% of large employers (1,000+ employees) cover at least one GLP-1 medication for obesity. Among small employers (fewer than 200 employees), that figure dropped to roughly 18%.

Coverage decisions among employer plans have been volatile. Many employers added GLP-1 coverage in 2022–2024 in response to employee demand. A significant number removed or restricted coverage in 2025–2026 as the annual cost — which can exceed $15,000 per covered employee — began to materially affect plan costs.

How to find out about your employer plan:

1. Request a copy of your plan's Summary of Benefits and Coverage (SBC) from HR
2. Search for "obesity," "weight management," "anti-obesity medications," or specific drug names in the excluded benefits section
3. Check your plan's drug formulary through the member portal
4. Ask HR directly: "Does our plan cover Wegovy or Zepbound for weight loss with a prior authorization?"

If your employer's plan excludes weight loss medications, escalation to HR may still be productive — particularly if supported by physician documentation of medical necessity. Some employers have granted coverage exceptions, especially for employees with significant comorbidities where the cost of untreated obesity exceeds the medication cost.

Medicaid Coverage

Medicaid GLP-1 coverage is the most variable of any payer category, determined at the state level.

As of 2026, approximately 13 states cover GLP-1 medications for obesity under Medicaid, each with their own eligibility criteria, prior authorization requirements, and formulary limitations. The majority of states do not cover weight loss GLP-1s under Medicaid.

If you have Medicaid, contact your state Medicaid program directly to inquire about current GLP-1 coverage for weight management. Coverage decisions change as state budgets and policy priorities evolve.

For diabetes indications (Ozempic, Mounjaro): Medicaid coverage for diabetes medications is broader, though formulary and PA requirements still vary by state.

The Savings Card: Your Backstop When Insurance Falls Short

For commercially insured patients (not Medicare or Medicaid), manufacturer savings cards dramatically reduce out-of-pocket costs when coverage is available — and in some cases when it is not.

Novo Nordisk Wegovy Savings Card

With qualifying commercial insurance: Copay can be reduced to as little as $0–$25/month. Eligible patients enroll at NovoCare.com or text SAVE to 83757 and present the savings card at the pharmacy.

Without insurance (cash-pay): The NovoCare program provides self-pay pricing — $149/month for Wegovy pill starter doses, $199/month for Wegovy injection starter doses (through June 2026), then $299–$349/month for ongoing doses. This is not the savings card — it is a separate self-pay program. Both require filling at a participating pharmacy or NovoCare Pharmacy.

Eli Lilly Zepbound Savings Card

Similar structure — with qualifying commercial insurance, Zepbound copay can be reduced to $25/month or less. LillyDirect provides cash-pay pricing of $299/month for the 2.5 mg starting dose through $449/month for maintenance doses.

HSA and FSA as a tax-effective tool

GLP-1 medications prescribed for a qualifying medical condition are eligible for HSA (Health Savings Account) and FSA (Flexible Spending Account) spending. This does not reduce the price but effectively reduces your after-tax cost by your marginal tax rate — typically 22–37% for most earners. At $349/month in ongoing Wegovy cash-pay cost, an HSA/FSA reduces effective cost by $77–$129/month compared to paying with post-tax dollars.

The Bottom Line: Your 2026 Insurance Strategy

If you have commercial insurance:

1. Check your formulary before choosing a provider
2. Choose a provider with a dedicated PA concierge team — Ro, WW Clinic, Calibrate, Mochi Health
3. Get the denial reason in writing if denied, then pursue peer-to-peer review
4. Enroll in the manufacturer savings card once approved — reduces your copay to $25 or less

If you have Medicare:

• With T2D: pursue Ozempic coverage now
• With cardiovascular disease: pursue Wegovy coverage under the cardiovascular indication
• With obstructive sleep apnea and obesity: pursue Zepbound under the OSA indication
• For weight loss alone: wait for the Medicare GLP-1 Bridge (July 2026) at $50/month

If your plan does not cover GLP-1s for weight loss:

• Self-pay options start at $149/month (Wegovy pill starter), $188/month all-in with GoodRx for Weight Loss subscription
• HSA/FSA reduces effective cost by 22–37%
• LifeMD, Sesame, GoodRx for Weight Loss, and Walgreens Weight Management are designed for self-pay access

The insurance landscape is changing faster than any other aspect of GLP-1 access. Check your plan annually during open enrollment — coverage that did not exist in 2024 may be available in 2026, and coverage available in 2025 may have been removed.